KRAS G12c Mutant
Cancers carrying the KRAS G12C mutation — the first KRAS variant with approved targeted drugs.
If KRAS G12c Mutant is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- First report of dual KRAS Y96C/Y96S resistance mutations detected by liquid biopsy in KRAS G12C-mutant metastatic colorectal cancer. · Oncologist · 2026-07-08
- Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in · Neoplasia · 2026-08-17
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
- FDA Grants Breakthrough Therapy Designation to Olomorasib for KRAS G12C-Mutant Advanced Pancreatic Cancer - Oncodaily · FDA Oncology (Google News) · 2026-08-05